Get the Stockscreener App
2.54
4.15%
-0.11
Taysha Gene Therapies Inc Stock (TSHA) Forecast
The Taysha Gene Therapies Inc (TSHA) stock price forecast for the next 30 days is generally negative, with an average analyst price target of $1.7839, representing a -29.77% decrease from the current price of $2.54. The highest analyst price target is $3.3938, and the lowest is $0.174.
Disclaimer: The information on this page is not intended to be financial advice. It is for general information only and should not be used to make any investment decisions. Please consult with a professional financial advisor before making any investment decisions.
12-Month TSHA Price Target
Average 4.657
(+83.34% Upside)
Is Taysha Gene Therapies Inc (TSHA) A Buy Now?
Oscillators
| Name | Value | Action |
|---|---|---|
| RSI(14) | 49.51 | Neutral |
| STOCH(9,6) | 27.22 | Neutral |
| STOCHRSI(14) | 9.043 | Buy |
| MACD(12,26) | 0.1164 | Sell |
| ADX(14) | 36.72 | Buy |
| William %R | -84.37 | Buy |
| CCI(14) | -128.80 | Sell |
Buy: 3
Sell: 2
Neutral: 2
Summary: Buy
Moving Averages
| Period | Simple | Exponential |
|---|---|---|
| MA10 |
2.7345
Sell
|
2.6804
Sell
|
| MA20 |
2.738
Sell
|
2.6265
Sell
|
| MA50 |
2.1511
Buy
|
2.3311
Buy
|
| MA100 |
1.8955
Buy
|
2.1193
Buy
|
| MA200 |
1.9733
Buy
|
2.1113
Buy
|
Buy: 6
Sell: 4
Neutral: 0
Summary: Buy
According to our latest analysis, TSHA could be considered a Strong Buy, with 17 technical analysis indicators signaling 9 Buy signals, 6 signaling Sell signals and 2 Neutral signals. This might be a good time to open fresh positions on TSHA, as trading bullish markets is always a lot easier
- RSI (Relative Strength Index): The RSI(14) value of 49.51 indicates that TSHA is neither overbought nor oversold. It suggests a neutral sentiment in the short term.
- STOCH (Stochastic Oscillator): The STOCH value of 27.22 indicates that TSHA is neither overbought nor oversold. It indicates a balanced market sentiment without any extreme buying or selling pressure.
- STOCHRSI (Stochastic Relative Strength Index): The STOCHRSI value of 9.043 indicates that TSHA is oversold. This suggests that TSHA price is at or near the lowest level relative to its recent price history.
- ADX (Average Directional Index): The ADX value of The ADX value of 36.72 suggests a moderate trend in the market. It indicates that there is more conviction behind the directional movement compared to lower ADX values. You should consider this as a potential opportunity to enter trades in the direction of the trend.
- CCI (Commodity Channel Index): A CCI(14) value of A CCI(14) value of -128.8 indicates that TSHA is oversold. This means that the price has moved significantly lower than its average, indicating a potential buying opportunity.
Long-term TSHA price forecast for 2025, 2030, 2035, 2040, 2045 and 2050
Based on our analysis about Taysha Gene Therapies Inc financial reports and earnings history, Taysha Gene Therapies Inc (TSHA) stock could reach $19.26 by 2030, $16.43 by 2040 and $87.00 by 2050. See the projected annual prices until 2050 of the Taysha Gene Therapies Inc stock below:
- Taysha Gene Therapies Inc (TSHA) is expected to reach an average price of $24.00 in 2035, with a high prediction of $24.28 and a low estimate of $24.17. This indicates an $844.97% rise from the last recorded price of $2.54.
- Taysha Gene Therapies Inc (TSHA) stock is projected to chart a bullish course in 2040, with an average price target of $16.16, representing an $536.19% surge from its current level. The forecast ranges from a conservative $16.38 to a sky-high $16.43.
- Our analysts predict Taysha Gene Therapies Inc (TSHA) to jump 2,992% by 2045, soaring from $80.52 to an average price of $78.55, potentially reaching $79.36. While $80.52 is the low estimate, the potential upside is significant.
- Taysha Gene Therapies Inc (TSHA) stock is expected to climb by 2050, reaching an average of $85.92, a $3,283% jump from its current level. However, a wide range of estimates exists, with high and low targets of $87.00 and $86.04, respectively, highlighting the market's uncertainty.
Taysha Gene Therapies Inc Stock (TSHA) Year by Year Forecast
Taysha Gene Therapies Inc Stock (TSHA) Price Forecast for 2025
Taysha Gene Therapies Inc Stock (TSHA) is expected to reach an average price of $5.2312 in 2025, with a high prediction of $10.29 and a low estimate of $0.174. This indicates an +105.95% rise from the last recorded price of $2.54.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| July, 2025 | $1.1099 | $0.174 | $3.3938 | -56.30% |
| August, 2025 | $0.6837 | $2.1937 | $1.1518 | -73.08% |
| September, 2025 | $3.1474 | $0.9596 | $1.7574 | +23.91% |
| October, 2025 | $5.5671 | $4.8434 | $5.5412 | +119.18% |
| November, 2025 | $6.8009 | $6.1031 | $6.7549 | +167.75% |
| December, 2025 | $6.2305 | $6.9746 | $6.2646 | +145.30% |
Taysha Gene Therapies Inc Stock (TSHA) Price Forecast for 2026
The predicted value for Taysha Gene Therapies Inc (TSHA) in 2026 is set at an average of $7.7582. Estimates vary from a peak of $9.1399 to a trough of $6.3765, indicating an +205.44% surge from the present price of $2.54.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2026 | $7.7343 | $6.3765 | $6.8543 | +204.50% |
| February, 2026 | $9.308 | $8.6752 | $8.358 | +266.46% |
| March, 2026 | $8.4318 | $9.0518 | $9.1399 | +231.96% |
| April, 2026 | $6.9015 | $7.8396 | $8.4577 | +171.71% |
| May, 2026 | $6.6852 | $6.9032 | $6.7574 | +163.20% |
| June, 2026 | $7.489 | $7.0411 | $7.359 | +194.84% |
| July, 2026 | $8.2986 | $7.4308 | $8.0086 | +226.72% |
| August, 2026 | $8.1624 | $8.3846 | $8.2765 | +221.35% |
| September, 2026 | $7.1421 | $7.3521 | $8.0383 | +181.18% |
| October, 2026 | $6.9958 | $7.0058 | $7.048 | +175.43% |
| November, 2026 | $6.4996 | $6.8496 | $6.8075 | +155.89% |
| December, 2026 | $7.3092 | $6.8755 | $7.1533 | +187.77% |
Taysha Gene Therapies Inc Stock (TSHA) Price Forecast for 2027
For 2027, Stockscan's Analyst expects the average price target for Taysha Gene Therapies Inc (TSHA) is $4.6381, with a high forecast of $7.1452 and a low forecast of $2.1311. This indicates an +82.60% increase from the last price of $2.54.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2027 | $6.963 | $7.063 | $7.1452 | +174.13% |
| February, 2027 | $6.9091 | $7.0434 | $7.0111 | +172.01% |
| March, 2027 | $6.5806 | $6.6164 | $6.7447 | +159.08% |
| April, 2027 | $6.2513 | $6.2756 | $6.4106 | +146.11% |
| May, 2027 | $5.9539 | $5.9539 | $6.076 | +134.41% |
| June, 2027 | $5.5156 | $5.5736 | $5.8108 | +117.15% |
| July, 2027 | $3.9373 | $4.5173 | $5.3895 | +55.01% |
| August, 2027 | $1.8811 | $2.1311 | $3.0633 | -25.94% |
| September, 2027 | $2.8408 | $2.487 | $2.3308 | +11.84% |
| October, 2027 | $2.2845 | $2.5195 | $2.5717 | -10.06% |
| November, 2027 | $2.6683 | $2.7083 | $2.6023 | +5.05% |
| December, 2027 | $2.2379 | $2.4079 | $2.4942 | -11.89% |
Taysha Gene Therapies Inc Stock (TSHA) Price Forecast for 2028
In 2028, Taysha Gene Therapies Inc (TSHA) is projected to reach an average price of $8.959, with a high projection of $17.88 and a low estimate of $0.0367. This indicates an +252.72% rise from the last price of $2.54.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2028 | $2.1917 | $2.2498 | $2.1158 | -13.71% |
| February, 2028 | $1.4254 | $1.9254 | $1.9476 | -43.88% |
| March, 2028 | $0.6151 | $0.0367 | $0.4667 | -75.78% |
| April, 2028 | $0.3611 | $0.0411 | $0.8211 | -85.78% |
| May, 2028 | $17.56 | $0.0633 | $15.17 | +591.34% |
| June, 2028 | $18.49 | $19.25 | $17.75 | +627.85% |
| July, 2028 | $17.18 | $18.36 | $17.88 | +576.57% |
| August, 2028 | $10.57 | $16.24 | $15.87 | +316.31% |
| September, 2028 | $6.2918 | $7.3818 | $8.4787 | +147.71% |
| October, 2028 | $5.6893 | $7.3275 | $5.8256 | +123.99% |
| November, 2028 | $14.05 | $10.93 | $10.69 | +453.10% |
| December, 2028 | $11.06 | $13.20 | $14.44 | +335.28% |
Taysha Gene Therapies Inc Stock (TSHA) Price Forecast for 2029
The 2029 price forecast for Taysha Gene Therapies Inc Stock (TSHA) is $14.58 on average, with a high prediction of $20.01 and a low estimate of $9.1431. This represents an +473.88% increase from the previous price of $2.54.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2029 | $12.45 | $11.64 | $12.38 | +389.98% |
| February, 2029 | $7.6431 | $9.1431 | $10.77 | +200.91% |
| March, 2029 | $11.42 | $9.4349 | $11.38 | +349.63% |
| April, 2029 | $14.16 | $13.69 | $13.83 | +457.40% |
| May, 2029 | $11.62 | $12.03 | $13.54 | +357.38% |
| June, 2029 | $11.92 | $11.15 | $10.22 | +369.48% |
| July, 2029 | $14.13 | $12.04 | $11.54 | +456.39% |
| August, 2029 | $16.34 | $14.19 | $15.52 | +543.38% |
| September, 2029 | $13.34 | $15.14 | $15.58 | +425.17% |
| October, 2029 | $19.59 | $15.60 | $18.03 | +671.21% |
| November, 2029 | $19.48 | $19.53 | $19.13 | +666.78% |
| December, 2029 | $20.45 | $20.02 | $20.01 | +705.26% |
Taysha Gene Therapies Inc Stock (TSHA) Price Forecast for 2030
Taysha Gene Therapies Inc Stock (TSHA) is expected to reach an average price of $18.32 in 2030, with a high forecast of $21.05 and a low forecast of $15.59. This signifies an +621.28% surge from the last price of $2.54.
| Month | Average | Low | High | Change from today's price |
|---|---|---|---|---|
| January, 2030 | $18.99 | $19.04 | $19.26 | +647.75% |
| February, 2030 | $21.00 | $19.36 | $19.80 | +726.79% |
| March, 2030 | $21.31 | $20.92 | $21.03 | +738.90% |
| April, 2030 | $20.51 | $20.64 | $21.05 | +707.30% |
| May, 2030 | $18.21 | $18.45 | $18.96 | +617.12% |
| June, 2030 | $17.70 | $17.94 | $17.41 | +596.94% |
| July, 2030 | $17.54 | $17.91 | $18.01 | +590.62% |
| August, 2030 | $18.49 | $18.04 | $18.24 | +627.92% |
| September, 2030 | $17.90 | $17.97 | $18.25 | +604.59% |
| October, 2030 | $16.57 | $16.78 | $17.34 | +552.21% |
| November, 2030 | $16.02 | $16.14 | $16.26 | +530.85% |
| December, 2030 | $15.49 | $15.59 | $15.66 | +509.88% |
1.91%
1.17%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):